Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 20,930 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-treatment Clear all

Conditions: Hereditary Angioedema Types I and II
Interventions: Ecallantide subcutaneous dosing; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Bladder Cancer
Interventions: CDX-1307 Vaccine Regimen, Chemotherapy; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 17
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more

Conditions: Diabetic Foot Ulcer
Interventions: Lavior Diabetic Wound Gel, Smith & Nephew Solosite Gel Hydrogel Wound Dressing; Drug
Lead sponsor: Lavior Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hemophilia B
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Opioid-Related Disorders
Interventions: Behavioral: the OPT-IN Intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Epidermolysis Bullosa
Interventions: ABH001, Control wound treatment; Biological · Other
Lead sponsor: Shire Regenerative Medicine, Inc.; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Phoenix, Arizona • Redwood City, California • San Diego, California + 3 more

Conditions: Lymphoma
Interventions: rituximab, bortezomib, yttrium Y 90 ibritumomab tiuxetan, Indium 111 ibritumomab tiuxetan; Biological · Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Hackensack, New Jersey • Chapel Hill, North Carolina

Conditions: Cancer
Interventions: methotrexate, methylprednisolone, prednisone; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Anastrozole, Letrozole; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neurofibromatosis Type 1
Interventions: HLX-1502; Drug
Lead sponsor: Healx Limited; Industry
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Conditions: HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
Interventions: TMC278, Efavirenz; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more

Conditions: Stress Disorders
Interventions: Guided Imagery for Trauma (GIFT); Behavioral
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anterior Cruciate Ligament Tear
Interventions: Regenexx SD, Exercise Therapy; Procedure · Other
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Opioid Withdrawal, Analgesia
Interventions: transcutaneous Auricular neurostimulation - Active, transcutaneous auricular neurostimulation - Sham; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Advanced Solid Tumors, Cancer, Hematologic Malignancies
Interventions: ABBV-621, Venetoclax, Bevacizumab, FOLFIRI; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: New Haven, Connecticut • Chicago, Illinois • Harvey, Illinois + 6 more

Conditions: Acute Respiratory Failure, Intubation Complication, Hypotension on Induction
Interventions: Fluid Bolus, No Fluid Bolus; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 11
States / cities: Birmingham, Alabama • New Orleans, Louisiana • Burlington, Massachusetts + 7 more

Conditions: Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
Interventions: Alvelestat (MPH966), Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 7 more

Conditions: Breast Cancer Female, Adriamycin Toxicity
Interventions: 10,000 steps, Usual Care; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest, PTSD
Interventions: Written Exposure Therapy; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Substance Use Disorders, Pain
Interventions: SBIRT-PM; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 9
States / cities: New Haven, Connecticut • West Haven, Connecticut • Augusta, Maine + 6 more

Conditions: Chronic Kidney Disease
Interventions: Pharmacist based QI program, Usual Care; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fatty Liver
Interventions: Polyunsaturated fatty acid (Opti-EPA), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: HIV Infections, Fatigue
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Foot Ulcers
Interventions: DermaPure™, Standard care; Other
Lead sponsor: TRx Wound Care Limited; Industry
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Miami, Florida • New York, New York + 3 more

Search by objective public record fields.

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Restoring Tissue and Evaluating Novel Treatments for Efficacy in Wounds

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

The OPT-IN Project

A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function

Regenexx™ SD Versus Exercise Therapy for ACL Tears

Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)

Pragmatic RCT of SBIRT-PM

A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers